(2-溴苄基)-乙基-二甲基-溴化铵 | 59-41-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (2-溴苄基)-乙基-二甲基-溴化铵
• 英文名称: Bretylium
• 英文别名: ZINC00001041；Aethyl-<2-brom-benzyl>-dimethylammonium；Aethyl-(2-brom-benzyl)-dimethylammonium；(2-bromophenyl)methyl-ethyl-dimethylazanium
• CAS: 59-41-6
• 化学式: C₁₁H₁₇BrN
• 分子量: 243.167
• InChiKey: AAQOQKQBGPPFNS-UHFFFAOYSA-N

物化性质

• 物理描述：
  Solid
• 熔点：
  238
• 溶解度：
  Freely soluble

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

ADMET

代谢

在人和实验室动物给药后，未发现代谢物。

No metabolites have been identified following administration in man and laboratory animals.

来源:DrugBank

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：溴苄铵已不再上市。由于在母乳喂养期间使用溴苄铵的已发表经验很少，加之其副作用发生频率高且药物不可获得，因此首选其他药物。 ◉ 对哺乳婴儿的影响：一位母亲在哺乳新生儿时，每8小时口服一次400毫克的溴苄铵对甲苯磺酸盐。她同时还服用每天25毫克的阿替洛尔、每天三次每次20毫克的普萘洛尔、每隔一天75毫克的螺内酯以及多种维生素、钾和镁的补充剂。婴儿在出生后60小时出现了被认为是与药物无关的黄疸，但后来消退。在前4个月的生命中，婴儿的体重增长和发育都适当。[1] ◉ 对泌乳和母乳的影响：截至修订日期，未找到相关的已发表信息。

◉ Summary of Use during Lactation:Bretylium is no longer marketed. Because there is little published experience with bretylium during breastfeeding, its high frequency of side effects, and its lack of availability, other agents are preferred. ◉ Effects in Breastfed Infants:A dose of 400 mg of bretylium tosylate every 8 hours was taken orally by one mother while nursing a newborn. She was also taking atenolol 25 mg daily, propranolol 20 mg three times a day, spironolactone 75 mg every other day and multivitamin, potassium and magnesium supplements. Jaundice, thought to be unrelated to the drug, occurred at 60 hours of age, but resolved. The infant had appropriate weight gain and development during the first 4 months of life.[1] ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

反应信息

• 作为反应物：
  描述：

  (2-溴苄基)-乙基-二甲基-溴化铵 、 (2-溴苯基)甲基-乙基-二甲基铵溴化物 、 、 sodium dodecyl-sulfate 、 水 在 氯仿 、 溴化钠 作用下， 以 氯仿 为溶剂， 25.0~43.0 ℃ 、17.77 kPa 条件下， 反应 25.0h， 生成 Bretylium dodecylsulfate
  参考文献：
  名称：

  Novel bretylium compositions and kits and their use in preventing and treating cardiovascular conditions

  摘要：

  本发明涉及包括布雷替琳作为活性成分的新型药物组合物和套装，以及利用这种新型药物组合物预防和/或治疗与心血管系统相关的疾病的方法。

  公开号：

  US20030119794A1

文献信息

• Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
  申请人：D'Sidocky Neil R.

  公开号：US20080242694A1

  公开（公告）日：2008-10-02

  Provided herein are Heterocyclic Compounds having the following structure: wherein R 1 , R 2 , X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.

  本文提供具有以下结构的杂环化合物： 其中R1、R2、X、Y和Z如本文所定义，包含有效量杂环化合物的组合物，以及治疗或预防癌症、炎症性疾病、免疫疾病、代谢性疾病以及通过给予患者需要的有效量杂环化合物来抑制激酶途径治疗或预防的疾病的方法。
• CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY
  申请人：Cerulean Pharma Inc.

  公开号：US20130196906A1

  公开（公告）日：2013-08-01

  Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.

  提供了关于使用CDP-治疗剂偶联物治疗疾病或紊乱的方法，例如自身免疫疾病、炎症性疾病、中枢神经系统紊乱、心血管疾病或代谢紊乱。还提供了CDP-治疗剂偶联物、包含CDP-治疗剂偶联物的颗粒以及包含CDP-治疗剂偶联物的组合物。
• Isoindole-imide compounds and compositions comprising and methods of using the same
  申请人：Muller W. George

  公开号：US20070049618A1

  公开（公告）日：2007-03-01

  This invention relates to isoindole-imide compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

  这项发明涉及异吲哚-亚胺化合物，以及它们的药物可接受的盐、溶剂化物、对映异构体和前药。这些化合物的使用方法和药物组合物已经公开。
• [EN] P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS P2X3 ET/OU P2X2/3 ET MÉTHODES ASSOCIÉES
  申请人：ASANA BIOSCIENCES LLC

  公开号：WO2018064135A1

  公开（公告）日：2018-04-05

  The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R7 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient.

  本公开提供了新颖的化合物和制备和使用这些化合物的方法。在一种实施例中，这些化合物具有如下式（I）的结构，其中R1-R7在此处定义。在另一种实施例中，这些化合物在调节P2X3或P2X2/3受体中的一种或两种的方法中是有用的。在另一种实施例中，通过向患者施用一种或多种化合物来治疗患者的疼痛是有用的。在另一种实施例中，通过向患者施用一种或多种化合物来治疗患者的呼吸功能障碍是有用的。
• Inhibitors of nedd8-activating enzyme
  申请人：IP Gesellschaft für Management mbH

  公开号：EP2764866A1

  公开（公告）日：2014-08-13

  The invention relates to an administration unit comprising crystalline form I of (1 S,2S,4R)-4-[(6-[(1R,2S)-5-chloro-2methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate (I-216) hydrochloride salt and to a packaging comprising the administration unit according to the invention.

  该发明涉及一种包含晶型I的(1S,2S,4R)-4-[(6-[(1R,2S)-5-氯-2甲氧基-2,3-二氢-1H-茚-1-基]氨基}嘧啶-4-基)氧基]-2-羟基环戊基}甲基磺酰胺(I-216)盐酸盐的管理单元，以及包括该管理单元的包装。